Amarin reported $-852K in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amarin USD -852K 7.26M Dec/2025
AstraZeneca USD 4.81B 894M Jun/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
DBV Technologies USD -47.4M 14.24M Mar/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 4.27B 430M Jun/2026